<DOC>
	<DOCNO>NCT01174043</DOCNO>
	<brief_summary>This research study look patient newly diagnose acute myeloid leukemia ( AML ) , AML return ( relapse ) , respond adequately previous treatment . Treating certain patient chemotherapy may benefit may cause harm benefit . The purpose study find effect ( good bad ) erlotinib patient AML .</brief_summary>
	<brief_title>Pilot Study Erlotinib Treatment Patients With de Novo Acute Myeloid Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Diagnosis AML history previous clonal/malignant hematologic disorder myelodysplastic syndrome myeloproliferative disorder . Newly diagnose patient age 70 old Relapses patient age 60 old time follow first relapse , patient consider candidate/not interested salvage chemotherapy . Refractory disease patient age 1859 fail least 2 line conventional chemotherapy ( 1 induction 1 salvage ) Patient must discontinue previous therapy AML least 14 day recover nonhematologic side effect therapy . Laboratory test must within protocolspecified range Patient must able swallow tolerate oral medication . Patients known central nervous system ( CNS ) leukemia spinal fluid cytology , flow cytometry image . History antecedent preleukemic hematologic disorder myelodysplastic syndrome myeloproliferative disorder . Diagnosis acute promyelocytic leukemia ( APL ) Patients require chronic anticoagulation , current smoker take rifabutin , rifapentine , phenytoin , carbamazepine , phenobarbital St. John 's Wort eligible . Patients active corneal erosion history abnormal corneal sensitivity test . Patients serious illness : significant ongoing active infection , New York Heart Association ( NYHA ) Grade II great congestive heart failure , unstable angina ( anginal symptom rest ) , new onset angina ( begin within last 3 month ) , myocardial infarction within past 6 month , cardiac ventricular arrhythmia require antiarrhythmic therapy , cerebrovascular accident within past 3 month , psychiatric illness would limit compliance study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Leukemia , Myelomonocytic , Acute</keyword>
	<keyword>Erlotinib</keyword>
</DOC>